Risk factors for hemolytic transfusion reactions resulting from ABO and minor red cell antigen incompatibility: From mislabeled samples to stem cell transplant and sickle cell disease

Blood Reviews ◽  
2020 ◽  
pp. 100719
Author(s):  
Eric A. Gehrie ◽  
Bipin N. Savani ◽  
Garrett S. Booth
Keyword(s):  
Risk Factors ◽  
Stem Cell ◽  
Sickle Cell Disease ◽  
Sickle Cell ◽  
Stem Cell Transplant ◽  
Cell Transplant ◽  
Red Cell ◽  
Cell Disease ◽  
Cell Antigen ◽  
Transfusion Reactions

scholarly journals Parental Awareness and Interest in Hematologic Stem Cell Transplant for Their Children With Sickle Cell Disease

2011 ◽  
Vol 17 (2) ◽  
pp. S256 ◽  
Author(s):  
P.M. Friedrich ◽  
K. Banholzer ◽  
F. Kim ◽  
E. Steinfield ◽  
L. Lehmann ◽  
...  
Keyword(s):  
Stem Cell ◽  
Sickle Cell Disease ◽  
Sickle Cell ◽  
Stem Cell Transplant ◽  
Cell Transplant ◽  
Cell Disease ◽  
Parental Awareness

Allogeneic hematopoietic stem cell transplant for sickle cell disease: The why, who, and what

Blood Reviews ◽  
2021 ◽  
pp. 100868
Author(s):  
Emanuela Cimpeanu ◽  
Maria Poplawska ◽  
Brian Campbell Jimenez ◽  
Dibyendu Dutta ◽  
Seah H. Lim
Keyword(s):  
Stem Cell ◽  
Sickle Cell Disease ◽  
Hematopoietic Stem Cell ◽  
Sickle Cell ◽  
Hematopoietic Stem Cell Transplant ◽  
Stem Cell Transplant ◽  
Cell Transplant ◽  
Cell Disease ◽  
Hematopoietic Stem

scholarly journals Reduced-Intensity Allogeneic Stem Cell Transplant for Sickle Cell Disease in Pediatrics: A Single Institution Experience

2018 ◽  
Vol 24 (3) ◽  
pp. S434-S435
Author(s):  
Michael J. Eckrich ◽  
Lisa Madden ◽  
Candace Taylor ◽  
Christina Matheny ◽  
Erica Frausto-Garcia ◽  
...  
Keyword(s):  
Stem Cell ◽  
Sickle Cell Disease ◽  
Sickle Cell ◽  
Stem Cell Transplant ◽  
Cell Transplant ◽  
Allogeneic Stem Cell Transplant ◽  
Cell Disease ◽  
Single Institution ◽  
Reduced Intensity

The ethics of a proposed study of hematopoietic stem cell transplant for children with “less severe” sickle cell disease

Blood ◽  
2014 ◽  
Vol 124 (6) ◽  
pp. 861-866 ◽  
Author(s):  
Robert S. Nickel ◽  
Jeanne E. Hendrickson ◽  
Ann E. Haight
Keyword(s):  
Stem Cell ◽  
Sickle Cell Disease ◽  
Hematopoietic Stem Cell ◽  
Sickle Cell ◽  
Hematopoietic Stem Cell Transplant ◽  
Stem Cell Transplant ◽  
Individual Autonomy ◽  
Cell Transplant ◽  
Cell Disease ◽  
Hematopoietic Stem

Abstract Hematopoietic stem cell transplant (HSCT) is the only cure for sickle cell disease (SCD). HSCT using an HLA-identical sibling donor is currently an acceptable treatment option for children with severe SCD, with expected HSCT survival >95% and event-free survival >85%. HSCT for children with less severe SCD (children who have not yet suffered overt disease complications or only had mild problems) is controversial. It is important to consider the ethical issues of a proposed study comparing HLA-identical sibling HSCT to best supportive care for children with less severe SCD. In evaluating the principles of nonmaleficence, respect for individual autonomy, and justice, we conclude that a study of HLA-identical sibling HSCT for all children with SCD, particularly hemoglobin SS and Sβ0-thalassemia disease, is ethically sound. Future work should explore the implementation of a large trial to help determine whether HSCT is a beneficial treatment of children with less severe SCD.

scholarly journals Pain and opioid use after reversal of sickle cell disease following HLA ‐matched sibling haematopoietic stem cell transplant

2018 ◽  
Vol 184 (4) ◽  
pp. 690-693 ◽  
Author(s):  
Deepika S. Darbari ◽  
Jaquette Liljencrantz ◽  
Austin Ikechi ◽  
Staci Martin ◽  
Marie Claire Roderick ◽  
...  
Keyword(s):  
Stem Cell ◽  
Sickle Cell Disease ◽  
Sickle Cell ◽  
Stem Cell Transplant ◽  
Haematopoietic Stem Cell Transplant ◽  
Haematopoietic Stem Cell ◽  
Cell Transplant ◽  
Cell Disease ◽  
Opioid Use ◽  
Matched Sibling
Sign in / Sign up

Export Citation Format

Share Document